Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Sector
Subsector
Location
total rounds
total raised
Sorrento Therapeutics
Sorrento Therapeutics is a biopharmaceutical company developing innovative therapies for cancer, autoimmune diseases and pain management.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Cend Therapeutics Inc.
Cend Therapeutics Inc. develops cancer therapies that overcome drug delivery barriers to solid tumors.
Sector
Subsector
Keywords
Location
total rounds
total raised
Ziopharm oncology
ZIOPHARM Oncology is a biotechnology company developing gene therapy, cell therapy, and cancer immunotherapy products.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Bristol Myers Squibb
announced date
price
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 26.10.2020. Their latest round Post-IPO Equity
Co-Investors
Investors11
Number of lead investors
Number of investors
OrbiMed
OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
SR One
SR One Capital Management is a biotech venture capital firm.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Nextech Invest
Nextech Invest is a venture capital and private equity firm that focuses on precision therapies in oncology.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders2
J. Jean Cui
J. Jean Cui, Ph.D. is a renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at Big Pharma and biotech companies (Pfizer, Pharmacia/SUGEN, etc.). Jean is the lead inventor of Pfizer’s precision oncology medicine, crizotinib, brand named XALKORI®. She created the drug’s novel chemical scaffold based on co-crystal structure and designed the final clinical compound crizotinib. XALKORI® was fast track approved by US Food and Drug Administration on August 26, 2011 for ALK positive late stage non-small cell lung cancer (NSCLC). In addition to the invention of crizotinib, Jean worked on several other oncology projects, including SUTENT®. She also created the clinical c-MET specific inhibitor PF-04217903 and designed the ALK second generation clinical compound PF-06463922. Her exceptional achievements in drug discovery and development have earned her many prestigious awards which include: the 38th National Inventor of the Year by Intellectual Property Owners’ Association (2011); Woman Worth Watching by Diversity Journal (2012); American Chemical Society Hero of Chemistry (2013); Pfizer Worldwide R&D Achievement Awards (2006 and 2012); Pfizer Innovation Award (2011); CABS K. Fong Award for Life Sciences (2013). Her story of crizotinib invention was featured in a Wall Street Journal article titled “Drug Discovery Gets an Upgrade” on April 16, 2012.
current job
organization founded
J. Jean Cui
Employee Profiles12
Adam D. Levy
Senior Vice President, Investor Relations and Corporate Communications
Homa Yeganegi
Senior Vice President, Project Team Leader and Head of Medical Affairs
Athena Countouriotis
President and Chief Executive Officer
Jeffrey P. Whitten
Vice President of Pre-Clinical Development
Activity
Recent News2
The graph reveals the ratio (%) of positive news articles in a chosen time range